Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This?

In the article, the author discusses issues in the use of allogeneic hematopoietic cell transplantation (HCT) as a curative therapy for myelodysplastic syndromes (MDS) in the U.S. as of September 2016. Also cited are the decision by the U.S. Centers for Medicare & Medicaid Services to allow Medicare coverage to allogeneic hematopoietic stem cell transplantation (HSCT) for MDS, and the importance of clinical trials in MDS.